Alliancebernstein L.P. cut its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 19.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,553 shares of the specialty pharmaceutical company’s stock after selling 11,800 shares during the period. Alliancebernstein L.P. owned 0.14% of AMAG Pharmaceuticals worth $643,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Bogle Investment Management L P DE acquired a new position in AMAG Pharmaceuticals during the fourth quarter valued at approximately $4,352,000. Geode Capital Management LLC boosted its position in AMAG Pharmaceuticals by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 377,479 shares of the specialty pharmaceutical company’s stock valued at $5,001,000 after purchasing an additional 5,452 shares during the last quarter. Spark Investment Management LLC acquired a new position in AMAG Pharmaceuticals during the fourth quarter valued at approximately $1,547,000. OppenheimerFunds Inc. boosted its position in AMAG Pharmaceuticals by 38.4% during the fourth quarter. OppenheimerFunds Inc. now owns 28,119 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 7,797 shares during the last quarter. Finally, Systematic Financial Management LP boosted its position in AMAG Pharmaceuticals by 31.9% during the fourth quarter. Systematic Financial Management LP now owns 111,535 shares of the specialty pharmaceutical company’s stock valued at $1,478,000 after purchasing an additional 26,945 shares during the last quarter.
NASDAQ:AMAG opened at $21.10 on Monday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.60 and a current ratio of 1.74. The company has a market capitalization of $739.73, a price-to-earnings ratio of -3.70 and a beta of 0.09. AMAG Pharmaceuticals, Inc. has a 12-month low of $11.93 and a 12-month high of $24.85.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.68. The firm had revenue of $158.30 million for the quarter, compared to analyst estimates of $158.84 million. AMAG Pharmaceuticals had a positive return on equity of 0.96% and a negative net margin of 32.66%. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.31) earnings per share. equities research analysts predict that AMAG Pharmaceuticals, Inc. will post -3.25 EPS for the current fiscal year.
Several brokerages recently commented on AMAG. BidaskClub raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. B. Riley increased their price target on AMAG Pharmaceuticals from $16.00 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, March 14th. Jefferies Group cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the company from $21.00 to $20.00 in a research report on Monday, March 5th. Piper Jaffray reissued a “hold” rating and set a $20.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, March 1st. Finally, Morgan Stanley increased their price target on AMAG Pharmaceuticals from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $23.91.
ILLEGAL ACTIVITY WARNING: This article was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://ledgergazette.com/2018/04/16/alliancebernstein-l-p-sells-11800-shares-of-amag-pharmaceuticals-inc-amag.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.